Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Damien B Ready

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|December 8, 2018
Specific MHC-I Peptides Are Induced Using PROTACsStephanie M Jensen, Gregory K Potts, Damien B Ready, et al.
Analytical Chemistry|September 23, 2021
Characterization of HLA-A*02:01 MHC Immunopeptide Antigens Enhanced by Ultraviolet Photodissociation Mass SpectrometryEleanor Watts, Gregory K Potts, Damien B Ready, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|December 8, 2018
Specific MHC-I Peptides Are Induced Using PROTACsStephanie M Jensen, Gregory K Potts, Damien B Ready, et al.
Analytical Chemistry|September 23, 2021
Characterization of HLA-A*02:01 MHC Immunopeptide Antigens Enhanced by Ultraviolet Photodissociation Mass SpectrometryEleanor Watts, Gregory K Potts, Damien B Ready, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Pageof 1